glucose concentrations if required. For each concentration category, individual samples with seven different hematocrit levels were generated based on the system's acceptable hematocrit range as indicated in the manufacturer's labeling: 10%, 15%, 25%, 42%, 55%, 60%, 65% (±2% for the midlevel sample [42%] and ±3% for the other samples, except for the samples at the lower and the upper limit [within +3% and −3%, respectively]).
Ten consecutive measurements were performed on each individual sample (combination of glucose concentration and hematocrit value) by using 10 different meters. Laboratory measurements were performed in duplicate with a hexokinase method (Cobas Integra® 400 plus; Roche Instrument Center, Rotkreuz, Switzerland) before and after measurements with the SMBG system.
For each individual sample the bias between the mean glucose result measured with the SMBG system (mean of 10 measurements) and the mean result of the laboratory method was calculated. To assess the hematocrit influence for each glucose concentration, the difference between the bias at higher and lower hematocrit levels and the bias at the midlevel was calculated (normalized bias).
The system showed ≤10 mg/dL and ≤10% difference (normalized bias) between the bias at higher and lower hematocrit levels and the bias at the midlevel (42 ± 2%) at glucose concentrations <100 mg/dL and ≥100 mg/dL, respectively ( Figure 1 ). The system fulfilled ISO 15197:2013 acceptance criteria with the investigated test strip lot within the hematocrit range given in the manufacturer's labeling.
Abbreviations
BG, blood glucose; ISO, International Organization for Standardization; SMBG, self-monitoring of blood glucose.
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https://orcid.org/0000-0003-4629-7754 Figure 1 . The difference between the bias at higher and lower hematocrit levels and the bias at the midlevel (42 ± 2%) was calculated (normalized bias) for three glucose concentration categories (blue: 30-50 mg/dL, red: 96-144 mg/dL, green: 280-420 mg/dL). The bias was calculated by using a hexokinase laboratory method. Lines connecting individual data points are provided for a simplified visualization and do not represent measured data. The system was tested within the labeled hematocrit range (10%-65%; indicated by dashed lines). Solid gray lines show ≤10 mg/dL and ≤10% limits at glucose concentrations <100 mg/dL and at glucose concentrations ≥100 mg/dL, respectively.
